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INTRODUCTION
Since Hippocrates, the guarantee of patients’ rights, dig-
nity and safety has been the object of consideration and 
debate. Recently, these discussions have been directed 
to the understanding that these rights represent human 
rights, with patients being considered within the context 
of their humanity. That is, the patient will be thought of 
not only as a biological being, but as the ultimate objec-
tive of science, placed above any pragmatic instrumental 
reason1. In the context of great social inequality, such as 
what is observed in Brazil, meeting Ethical principles is 
particularly challenging, both in research as in the practice 
of Epidemiology.  
The Greek word ethika comes from ethos and refers to 
an individual’s character and the morality of his action. 
The word morality comes from Latin and means to 
make the best choice among the possible ones, considering 
all the circumstances where there are conflicts between dif-
ferent values2. These conflicts occur in all clinical and public 
health situations that involve decisions, either at the level of 
the individual, collective, institutions or legal entities. 
The disclosure of experiences carried out by the Nazis, 
especially with the Jewish population during the World 
War II led to an increased pressure to guarantee the dig-
nity of research subjects3. An important landmark was the 
Declaration of Helsinki, which established ethical prin-
ciples and procedures, leading to the creation of courts in 
international organs such as the Council for International 
Organizations of Medical Sciences – CIOMS, of the World 
Health Organization and the United Nations Educational, 
Scientific and Cultural Organization – UNESCO4-6.  For ep-
idemiological researches, CIOMS has launched the Univer-
sal Declaration on Bioethics and Human Rights7. In Brazil, 
the regulatory organ for Ethics in Research is the National 
Council of Health (Conselho Nacional de Saúde – CNS) 
that works through the National Research Ethics Commit-
tee (Comissão Nacional de Ética em Pesquisa – CONEP), 
which coordinates the National System of Ethics in Re-
search (Sistema Nacional de Ética em Pesquisa- SISNEP).
Ethics permeates all social behavior and any profes-
sional practice, but research with human subjects requires 
the formal appreciation of their respective protocols by 
a third party to verify the meeting of established ethical 
principles. In the healthcare scenario, this evaluation is 
carried out by peers that constitute Research Ethics Com-
mittees, which are particularly important in intervention 
researches. However, Ethics in Research comprehends all 
investigations with human subjects, experimental or non-
experimental, qualitative or quantitative, carried out with 
patients or disease-free individuals. 
This scope extension is the object of controversy and 
debate between researchers and society, especially regard-
ing ethnographic or social studies, for which there is no 
tradition regarding the scrutiny of ethical aspects by the 
Ethics Committee. When the research is in the Public 
Health area, of which objective is interdisciplinary, the 
challenges are even bigger. Studies can involve ethno-
graphic and intervention components, interconnected, or 
associated with the daily practice of subjects, distant from 
academic formalism and clinical experiments. However, 
epidemiological researches commonly require an exten-
sive number of participants, use of questionnaires and 
have a limited potential risk for the subjects. 
This article aims at presenting the theoretical prin-
ciples and bases of Ethics in Research employed in the 
Brazilian standards, synthesizing its fundamental prin-
ciples, regulatory landmarks, institutional structure and 
specificities of Epidemiology applied to the Collective 
Health field. 
PRINCIPLES OF ETHICS IN RESEARCH IN HUMAN SUBJECTS 
The fundamental principles of Ethics in Research are the 
autonomy, non-maleficence, beneficence and justice, 
within a common parameter, which is of that of respect 
to human dignity8. It is not only about following recom-
mendations or norms, but the consideration, on the part 
of investigator and team, of the ethical implications of the 
research project.
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AUTONOMY
It refers to the self-government or self-management that 
has been extended to individuals, by incorporating the 
rights of freedom, privacy, individual choice, free will 
and self-determined behavior. In the research field, that 
implies that the subjects have assured their rights to de-
cide on their participation, free of any coercion or pres-
sure. Within this principle, it is implicit that it is the in-
vestigator’s obligation: 1) to tell the truth; 2) respect the 
privacy; 3) protect the obtained information; 4) to obtain 
consent for eventual interventions, collection and storage 
of biological material and personal information, includ-
ing images, such as videos, photographs, recorded voice 
material, among others; 5) when requested, contribute 
to the decision-making, based on his or her technical 
knowledge. 
The participation does not mean only “entering” the re-
search, but the right to remain or leave, at any phase. This 
is important, when there is a restriction in the capacity 
of making decisions or individual freedom, such as cases 
with consciousness level or cognitive capacity impairment, 
institutionalized individuals or inmates. In these cases, the 
authorization of the legal, institutional or individual tutors 
is necessary, as well as of family members. Researches with 
military personnel or other institutions with a strong hier-
archic organization require extra care regarding decision 
to participate, which must be separated from the discipline 
and structure of the institutional power. 
As the decision to participate in researches must be the 
result of the individual’s exclusive choice, it is mandatory 
that the individual knows about the research purposes, 
reason for the selection, procedures, potential risks, bene-
fits and harms, and especially, to whom the research inter-
ests. This information and participation decision process 
is called “consent”. Therefore, the subjects are contacted, 
informed about the research and invited to participate. If 
they agree to do so, the Free and Informed Consent Form 
(FICF) must be presented to them, which must be writ-
ten in a language and style that is appropriate to the target 
population. On the one hand, this is not always easy to do, 
due to the nature of some researches which are complex 
and unusual, di cult to comprehend even in the academic 
environment. On the other hand, consent may sometimes 
be di cult to obtain, as in clinical emergency situations, 
or in multicentric international studies, in which the FICF, 
appropriate for the headquarters, might not be adequate 
for the requirements of other countries.  
Cultural dierences about the understanding of proto-
cols and even inconsistencies in the translation of instru-
ments can occur, limiting the eectiveness of their use. It 
is important to remember that declared and formal insti-
tutional agreement is always required when the research 
involves institutions, either at the recruiting of individuals 
or data collection phase. 
In Brazil, the participation of Native Brazilians requires 
the approval of the tribe, through its chief representative 
and of the National Native Brazilian Foundation (Funda-
ção Nacional do Índio). 
Population-based researches or those developed in 
communities can benefit from the project presentation to 
discuss it with their members and thus, carry out adjust-
ments in their strategies to meet the collective and indi-
vidual expectations. Visual material and wide discussions 
in workshops and seminaries can be used to allow a bet-
ter understanding and comprehension by the subjects, 
and therefore, more conscious decisions. That represents 
a higher level of quality regarding individual consent, both 
regarding the operational aspects and the potential im-
pact of results. That is the core of the “genuine consent” 
concept, which appeared in 1995 at the Nu eld Council 
on Bioethics, and puts the perfectly informed consent 
into perspective, substituting it by the idea of an eort to 
achieve the best possible communication and transpar-
ency9. Ways to employ this concept have been increasingly 
discussed, such as the broad dissemination of the research 
in the media, i.e., its objectives, methods, scope and ex-
pected impacts9. 
The individual, classic, formal, identified and signed 
consent is relativized in researches carried out by phone 
or the internet, and the electronic form of the FICF might 
be used, with a digital signature or not. Interviews carried 
out by phone allow, almost exclusively, obtaining the FICF 
through verbal authorization, except when personal con-
tacts are complementary involved. 
The FICF must not be too extensive and has to include 
the main investigator’s data, its institutional a liation, ad-
dress, telephone and alternatives for contact. The eective-
ness of the FICF is questionable when the study popula-
tion is within survival thresholds, has limited reading or 
understanding capacity. When the subjects are illiterate, 
someone trusted by the interviewee can be included as a 
witness to collaborate in their decisions. 
BENEFICENCE
Researches that are aimed at the participants’ benefits are 
ethically acceptable. Examples of such benefits are the im-
provement of the knowledge on diseases, cures and reha-
bilitation. Less evident, especially for the lay public, are 
the benefits of basic research, on procedures or methods. 
Benefits can have a stronger impact on the collective and 
not exclusively on the individual plane, as in Public Health 
researches aimed at collective risks and public policies. 
It is noteworthy to consider the association between 
the public and the private, and between the research fi-
nancial support and objective. Although, in many coun-
tries, the health research has significant financial support 
from the public sector, either institutions or workers, 
the manufacturing and commercialization of products 
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are commonly the responsibility of the private sector10. 
Hence, the knowledge and technologies produced with 
public resources are not always available to the popu-
lation, whose contribution through taxes made the re-
search possible. As evidence of that fact is the lack of 
medications for AIDS in African countries, which have 
broadly participated in researches that allowed drugs to 
be manufactured and commercialized. Some therapeu-
tic assays were interrupted when the treatment eective-
ness was acknowledged, leaving the participants without 
access to the drugs used in the research itself10, stirring 
up the public opinion that called attention for the need 
to guarantee the treatment11. Thus it is the investigator’s 
responsibility, when formulating the investigation ques-
tion, to consider to whom the results interest and how 
the participants will potentially benefit, either individu-
ally or collectively. 
Finally, it must be observed there are always risks 
and these must be considered in relation to potential 
benefits, seeking to maximize the latter, while minimiz-
ing damage and risks, guaranteeing that maleficence and 
beneficence are equally shared between the participants. 
NON-MALEFICENCE
It comprehends the participant’s guarantee that he or she 
will not suer any damage during the research, i.e., guar-
antee that predictable risks are prevented. Desperate situ-
ations, of depletion of available therapeutic resources and 
hope of cure with treatments still in experimental phases 
can lead to the search and even pressure on the part of pa-
tients to participate. The expectation of treatments that are 
not available in the market and free of costs has attracted 
many volunteers12. 
In addition to the physical eects, but not less severe, 
there are psychological, intellectual, social or spiritual dis-
comforts. It is important to consider that damages to the 
image can be caused simply by disclosing the participation 
in the investigation.
Questions on past traumas can cause suering by be-
ing recalled. Participants can also be emotionally touched 
or feel embarrassed by sensitive themes, such as religious 
beliefs or sexual behaviors. 
Mental illness sometimes occurs without the awareness 
of the patient or is the object of denial. The identification 
and disclosure of a diagnosis, within a research context, 
can cause discomfort or embarrassment. It is important to 
pay attention to researches conducted in multiple phases, 
when the progression between the phases results from di-
agnoses, which can compromise their confidentiality. It 
is worth remembering that the risks for the participants 
caused by the research can be at the population level, such 
as in environmental interventions, or individuals ones, 
such as the collective stigma caused by the participation in 
the research itself13. 
It is noteworthy that the pharmaceutical industry has 
a large participation in the economy. When the research is 
carried out in poor countries and the responsibility of the 
initiative and performance belongs to other countries, 
the consequences can be disastrous. Therefore, the need to 
keep the poor populations safe10,14,15.
JUSTICE
The principle of justice means that the research subjects 
must have guaranteed their equality of rights. Still, under 
the perspective of equity, relative to unequal treatments, 
but compatible with individual or social inequalities to 
overcome them.
The concept of equity broadens that of equality, which 
considers all subjects equal. In addition to the concept of 
equity, the concept of merit – what is deserved – and that 
of prerogative – that what someone is entitled to, are im-
portant. Therefore, the principle of justice implies in just, 
equal and appropriate treatment, taking into consideration 
what is due to people. Thus, the research must minimize 
the onus for vulnerable subjects. 
Every subject must have, in principle, the same chance 
to be selected, obviously guaranteeing coherence with 
the objectives and the methodology of the research. Any 
exclusion must have a justification in the investigation, 
without reflecting discrimination or negligence. The FICF 
must contain the reason for the choice of the individual, 
and what the individual represents in the study popula-
tion. One example of injustice in research in Brazil was a 
study on malaria, in which the participants, who belonged 
to the lower socioeconomic classes, received remunera-
tion. The project was approved by CONEP and Ethical 
Committees of the institutions in charge of the project in 
Brazil and another country, but the protocol did not men-
tion the remuneration to the participants16.  
Other principles and guidelines have been the object of 
discussion by several authors, such as the specific respect to 
ethnical17 and religious18 diversity, scientific validity and so-
cial value19, among other aspects, such as informed consent, 
non-exploration, essentiality, privacy and confidentiality, 
risk precaution and minimization, professional competence, 
responsibility and transparence, distributive justice, institu-
tional arrangements, public domains and adherence20.
REGULATORY LANDMARKS AND INSTITUTIONS RELATED TO 
ETHICS IN RESEARCH IN BRAZIL
First, the investigators must follow the dispositions con-
tained in the Ethical Codes of their respective professional 
categories and the specific norms of Ethics in Research, of 
which main document in Brazil is Law 196 of the National 
Council of Health – CNS, which created CONEP, respon-
sible for monitoring Research Ethics Committee (REC). 
Several other complementary laws followed Law 196 and 
can be consulted at the electronic address of CONEP. 
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The protection of research subjects’ rights is one of 
the attributions of CNS, which, through CONEP, have 
strengthened and consolidated the performance of pub-
lic organs in establishing norms and monitoring them. 
CONEP is a collegiate subdivision of CNS, which has 
consultation, deliberative, normative and educational 
characteristics and administrates SISNEP, an online sys-
tem that records researches involving human beings. 
The planning of a research requires explicit disclosure 
of the ethical aspects and thus, the investigator must 
have, as part of his formation, the knowledge of princi-
ples and recommendations contained in international in-
struments and regulatory landmarks of the country. This 
must be contained in a section entitled Ethical Aspects 
(Box 1) and be the object of discussions and reflections 
on the part of the entire team. It is unfortunate that this 
section is usually limited to information that a REC has 
approved the study. In Box 2, some questions are present-
ed that can be employed in these discussions. When there 
is a great social interface of the research, the reading of 
the questions in Box 1, which were adapted from Jesani 
& Barat21, is recommended. 
INCLUSION BY GENDER, AGE GROUPS AND ETHNICITY
Participants of the present study will not be excluded by gender, ethnicity or skin color. The exclusion of the unem-
ployed or other categories not formally defined as workers, such as students and family members that are not work-
ing or looking for a job, is justified by the study objective and is detailed in the specific Methods section. 
HUMAN SUBJECTS 
This project was reviewed and approved by the Ethics Committee of the INSTITUTION (Prot. N. xx, date), as well 
as of the collaborative INSTITUTIONS, INSTITUTION A (Prot. No. xxx date) and INSTITUTION A (Prot. No. 
xxx date). The investigators have considered the question of using kindness when handling sensitive aspects such as 
sexual harassment, psychiatric symptoms and ethnicity that are evident at the FICF regarding the language employed 
in the questionnaires and instructions for the interviewers contained in the Manual of the Interviewer. 
RESEARCH MATERIAL TO BE OBTAINED
It consists only of data obtained through questionnaires applied by interviewers, containing family, social, occupa-
tional and health-related information.
SUBJECT RECRUITING
It has been shown in the Methods section that all residents of houses located in the studied areas will be selected 
for the research, a strategy that has been successfully employed in previous studies. The voluntary nature of subject 
participation and the procedures to guarantee data confidentiality will be described to the participants. Verbal con-
sent will be obtained by interviewers and the FICF will be signed. Witnesses’ signatures will be provided for those 
who refuse to sign the FICF. Permission to access medical records and verbal permission will also be obtained, and 
information regarding further visits at future phases of the study will be given. 
POTENTIAL RISKS
There is no indication that the study procedures oer any risk to the participants. However, reports of past disagree-
able experiences, such as O AGRAVO EM ESTUDO, can cause some psychological discomfort, although it can in-
crease the awareness of danger in the workplace. This discomfort can be minimized by acknowledging that this can 
be a relevant contribution for the community and can support the adoption of work protection measures. Previous 
experiences with the population of this city have demonstrated a high degree of receptiveness regarding this type of 
research. 
PROCEDURES AGAINST RISKS
Participants’ individual names shall be employed only for logistic purposes when conducting the study, such as iden-
tifying people’s addresses in order to apply questionnaires and re-visits at the follow-up.  Once revised and processed, 
the names shall be removed from the questionnaires and filed separately. A single number of identification will be 
attributed and used throughout the analysis. The study code shall be kept in locked cabinets, of which keys shall  
be under the responsibility of the main investigator. Individual identifiers shall not be employed for typing, analysis 
and generation of reports. 
Box 1 – Examples of “Ethical Aspects of Research Project” sections based on questionnaires
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Dimensions Questions Dimensions Questions
1 - Essentiality and 
maximization of 
public interest and 
social justice 
Are the investigation questions and expected 
answers essential for the improvement of 
population’s health status? 
Will the results of this research bring benefits 
to society? Will they contribute to social 
justice?
7 - Non-exploration Are we righteously using the time and 
information provided by the participants, 
in order not to impair their gains or 
dignity? Do we guarantee that unnecessary 
risks are not involved? Have the least-
experienced investigators had their work 
acknowledged and justly treated and have 
their authorships been considered at the 
publications? 
2 - Respect to 
vulnerable groups
Are vulnerable groups of subjects, such as 
native populations, inmates, institutionalized 
subjects, children, the elderly, mentally-ill 
individuals, individuals with limited cognitive 
capacity or legal custody involved in this 
research? If yes, have we specified the 
justifications in detail?
8 - Public domain Is the research project going to be 
disclosed through the appropriate means 
of communication to the concerned 
subjects and participants, whether they are 
individuals or collectivities? 
Are the results going to be disclosed to the 
scientific community, service managers 
and the study subjects? 
3 - Knowledge, 
capacity and social 
commitment 
Does the team responsible for the 
investigation have the capacity, knowledge 
and commitment with society required to 
conduct this research?
9 - Public 
responsibility and 
transparency
Have mechanisms been established to 
guarantee complete honesty regarding 
resource use, financial sources, eventual 
conflict of interests and accountability 
transparency? How will this information be 
available to the public? 




Do we guarantee autonomy protection and 
the right to voluntary participation, with 
clear awareness about the objective and 
procedures, risks involved and the use of 
knowledge to all research subjects? Do we 
adopt procedures to guarantee the rights and 
dignity of the research subjects, whether they 
are individuals, institutions or legal entity?
10 - Authorship 
and disclosing of  
results
Have the authorship and co-authorship 
criteria of reports and publications been 
defined and agreed upon by the research 
team? Will co-authorship be granted to the 
less-experienced members of the team?
5 - Privacy, 
anonymity and 
confidentiality
Do we adopt procedures 
that will guarantee the participants’ privacy, 
anonymity and the confidentiality of the 
information used in the research? 
Are all the team members aware of and 
committed with this guarantee? 




Are the financial support institutions, 
sponsors, executors and co-executors 
aware of their role and attributions in the 
research? 
Have the team members been informed 
of and do they share ethical and scientific 
responsibility involved in the research? 
Has the protocol containing all relevant 
information been submitted to a Research 
Ethics Committee, when applicable?  
6 - Precaution and 
risk minimizing
Have all possible risks been identified, 
with their respective degree and effects? 
Have these risks been clearly explained to 
participants, team and subjects? What has 
been done to minimize these risks? What 
measures will be adopted to discontinue the 
study if unexpected risks occur? 
What measures will be adopted to repair 
problems caused by the research, in case 
they occur?
12 - Data or 
material custody 
and sharing 
Will the research data be stored, while 
guaranteeing the privacy of study subjects 
and of what is stated in the FICF? 
Will the biological material be adequately 
stored and will the institutional 
responsibility be defined according to the 
Laws of the country?
Source 1 - Based on Jesani A, Barai T. Ethical Guidelines for Social Science Research in Health. http://www.hsph.harvard.edu/bioethics/guidelines/ethical.html, 2003. 
Source 2 - Adapted from Santana V & , Castilho EA, Ética na Pesquisa e Práticas Epidemiológicas. in Almeida-Filho N, Barreto ML, Roquayrol Z. Epidemiologia & 
Saúde: Fundamentos, Métodos e Aplicações. Rio de Janeiro: Ed Guanabara Koogan (In press). 
Box  2 – Questions on Ethics in Research with human subjects in the social science scenario, aiming at the investigator’s 
consideration when creating projects. 
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CONFLICT OF INTEREST
The handling of several functions by the same investigator, 
as it occurs in the private sector, such as in the pharmaceu-
tical industry or the manufacturing of substances known 
to be pathogenic, in addition to the private financial sup-
port given to researches or investigators, can lead to the so 
called conflict of interest. This means that certain results 
of a research are of the interest of the financial supporter, 
or even of the investigator. That erases or attenuates the 
required “neutrality” of those responsible for the research. 
The interests can be financial, status-related, of au-
thorship, commitment with advisors, heads of depart-
ments, research groups, among others22. But the existence 
of conflicts of interest does not always mean frauds or 
biases. In general, transparency is required related to the 
disclosure of connections regarding the investigators or 
the research, in the protocol and respective publications, 
specifying sources of support and funding. To overcome 
problems with the non-publication of clinical trials of 
which results are unfavorable, journals have required the 
protocols of these studies to be previously registered prior 
to their accomplishment, in systems such as CONSORT. 
The non-publication of negative findings impairs mainly 
the conclusions of the meta-analyses and consensus pan-
els, commonly employed in the consolidation of evidence 
used in decision-making. 
Conflicts of interest can also occur in the public sector, 
due to political or corporatist problems, especially regard-
ing the disclosure of results that can have a negative impact 
on the prestige of politicians, technicians, managers, or in-
terfere in the public opinion23.  
ETHICS IN EPIDEMIOLOGY
Epidemiological practice is closely associated with Public 
Health, which reflects on the overlapping of their ethical 
questions. These practices involve academic research and 
are performed in response to service demands for the epi-
demiological surveillance, in auditing processes or in inves-
tigations carried out by legal requirement to investigate a 
complaint. In these last cases, the results will be employed 
as evidence. In epidemiological surveillance, some common 
ethical dilemmas circumscribe situations where conflicts 
emerge between individual rights and public interest. One 
example is the need to control transmissible disease out-
breaks, which might require the collection of samples for 
laboratory assessment of information through personal in-
terviews, but it is the individual’s decision to provide them. 
The consequences of a possible refusal aect not only 
the health of individuals, but also of the population. 
Quarantine is a situation in which the freedom of indi-
viduals is regarded as secondary for the common good, 
to prevent disease transmission and environmental dam-
age, among others. The control of communicants of cer-
tain infectious diseases can lead to di culties to preserve 
anonymity and the confidentiality of information, also 
causing personal embarrassment. 
These examples illustrate contradictions between the 
guarantee of basic ethical principles, especially of auton-
omy, in epidemiological practice. In Brazil, the case inves-
tigation by the Epidemiological Surveillance, according 
to Law #6.295/75 and Decree #78.231/76, not implies in 
obtaining consent, because it is mandatory. The registra-
tion of the correct diagnosis and the notification to the 
National Notification System (Sistema Nacional de Agra-
vos de Notificação – SINAN) are also obligatory, and is the 
professional responsibility of the physician. However, the 
aforementioned conditions regarding the respect to pri-
vacy, confidentiality and anonymity must be guaranteed. 
Notice that anonymity and confidentiality are not restrict-
ed to the nominal reference of subjects, but to all forms of 
result presentation that allows the identification of partici-
pants, either individuals or legal entities. 
Another relevant situation is when the investigator 
identifies among the participants cases of criminal oenses, 
such as physical or sexual abuse of children that involves 
close relatives and that must be reported to the competent 
authorities, guaranteeing the rights of the victims and their 
integrity. That depends on the degree of consolidation, in-
fra-structure and capacity of local institutions. 
 The epidemiological research can oer risks to the 
authors. The publication of results that are unfavorable to 
certain groups or interests can threaten the physical in-
tegrity or the rights of the investigators. Public or anony-
mous threats, sometimes violent ones, as psychological or 
economic pressure, such as dismissal, loss of functions or, 
indirectly by the non-approval of project funding or publi-
cation, have been described22.  
In the United States of America, laws guarantee the 
rights of investigators or individuals that denounce per-
sons in charge or situations that threaten the health of 
the population. Some associations and social movements 
support those who denounce (whistleblowers), guarantee-
ing their safety and encouraging this practice, both in the 
academic community and among citizens. For instance, 
workers that denounce bad working conditions and how 
these aect their health have the legal guarantee that they 
will not suer retaliations. More information can be found 
at www.whistleblowers.org.
The disclosure of research results, especially those that 
received public funds, is considered an obligation of the 
investigator and of ethical behavior, of responsible con-
duct when handling the obtained information, giving back 
the knowledge to those who made it possible. 
This is not always possible, considering the informa-
tion nature, the population dispersion, among others, but 
the investigators must seek ways to make it feasible. Re-
sults of interest for the participant’s health must be imme-
diately handed. 
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A recent discussion deals with the availability of re-
search data to the participants and public access to da-
tabases, but it is di cult to warrant anonymity in these 
circumstances. The inappropriate handling of data, to 
skew results in the direction of the desired outcome, 
has also been described as one of the common ethical 
questions in research. Large-scale studies are especially 
susceptible to the manipulation of relevant information, 
such as the ones that reveal weak points or biases in their 
development. 
Another relevant aspect is that of intellectual prop-
erty21, a question that arises mainly when the research re-
sults from a collective eort, common in Epidemiology. 
An ethical behavior is expressed in the explicit con-
tribution of each collaborator, in the project phases, de-
scribing the intellectual contribution of each participant 
and the declaration of authorship criteria for each study 
product. The relationship between advisor and advisee, 
at any level of learning, must be guided by the respect 
to the dignity of the professor/student21, acknowledging 
the scientific contributions and authorship. This ethical 
behavior must be reflected in mutual solidarity and sup-
port. The participation of coauthors that did not contrib-
ute scientifically has been discouraged. 
Some journals have requested the explicit description 
regarding the participation of each author. Moreover, as 
a measure of precaution, investigators must not disclose, 
mainly to the media, the preliminary results of a study 
before a peer-conducted review is carried out. 
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